

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 16825

APPENDIX C (TABLE II)

OUTCOMES OF DARVON USE: SUICIDE ATTEMPTS AND GESTURES, PROPOXYPHENE
DEATHS AND PRESCRIPTIONS: RELATION TO AGE

CATEGORY	DATE SOURCE	AGE GROUP						
		0-9	10-19	20-29	30-39	40-49	50-59	60+
I. Mentions for propoxyphene	NDTI	0.4%	6.5%	33%		28%		33%
IIa. ER Visits related to Propoxyphene n = 408	FDA Poison Center	23%	29%	31%	8%	4%	3%	1%
IIb. ER Visits for Suicide, Gestures (1% lethal)	FDA Poison Center		37%	40%	11%	6%	4%	1%
<u>DEATHS</u>								
III. FDA: Probable Suicides reported Total = 173 83M: 84F	FDA ADR Reports	0	22%	37%	20%	14%	8%	
IV. FDA: Probable "Accidental" Total = 48 19M: 28F	FDA ADR Reports	13%	13%	34%	17%	6%	2%	
V. Finkle data Propoxyphene Associated Deaths (all) n = 1022 45M: 55F	Finkle, et al, <u>J. Forensic</u> <u>Sci</u> 1976	2%	12%	27%	21%	20%	11%	8%
VI. DEA Data	DEA							
WM 20% BM 5% WF 44% BF 16%	ER Visits 1/75-8/78		24%	41%	19%	10%	6%	